• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Practical Matters: Completely stage dogs with lymphoma to select therapy and help determine the prognosis

November 1, 2004
Kevin A. Hahn, DVM, PhD, DACVIM (oncology)

Selecting appropriate chemotherapy protocols and successfully treating dogs with lymphoma require complete clinical staging of the disease.

Selecting appropriate chemotherapy protocols and successfully treating dogs with lymphoma require complete clinical staging of the disease. A complete blood count, serum chemistry profile, and urinalysis, along with a two-view survey radiographic examination of the thorax and abdomen, will help you provide a prognosis to a pet owner. Core or excisional biopsy of one or more lymph nodes is essential before starting treatment.

Most oncologists and reports suggest that dogs with stage I (single node involvement) and II (regional node involvement) lymphoma fare better than those with stage IV (liver, spleen, other visceral involvement) and V (bone marrow, ocular involvement) lymphoma. Dogs with high- to medium-grade stage III (generalized lymph node involvement, multicentric) lymphoma often have good initial responses to treatment. However, cures are still rare, and most dogs survive an average of one year after treatment, with 25% living two years or longer.

Advertisement

It is important to realize that some dogs survive long-term despite having negative prognostic indicators and that some dogs that do not have the negative indicators do not have long-term survival. Dogs that are clinically ill have a poorer prognosis than those without systemic illness. T-cell tumors generally warrant a poorer prognosis than B-cell tumors do. Cutaneous, alimentary, and bone marrow sites of involvement are associated with a poor prognosis, as are male sex, hypercalcemia, and a history of corticosteroid therapy. Dogs weighing less than 33 lb (15 kg) reportedly have a better prognosis than larger dogs, likely because administering chemotherapy drugs on a m2 basis provides a relatively larger area under the curve for the drugs and, hence, higher overall drug exposure in small dogs.

Kevin A. Hahn, DVM, PhD, DACVIM (oncology)

Gulf Coast Veterinary Specialists

1111 W. Loop South, Suite 150

Houston, TX 77027

Related Content:

Oncology
Feline oral cancer is the focus of a new study
Feline oral cancer is the focus of a new study
Advances in the detection, characterization, and monitoring of cancer in pets
Advances in the detection, characterization, and monitoring of cancer in pets
Volition's Nu.Q Vet Cancer Test now available for preorder at point-of-care via Heska Corporation
Volition's Nu.Q Vet Cancer Test now available for preorder at point-of-care via Heska Corporation

Advertisement

Latest News

Xylazine moves from the stables to the streets

DEA reports widespread threat of fentanyl mixed with xylazine

3 Must-reads for National Poison Prevention Week

UC Davis study on eye diseases in kittens

View More Latest News
Advertisement